Novoprotein(SH:688137)2025-04-28 16:15Financial Performance - The company's operating revenue for Q1 2025 was ¥33,444,619.29, representing a 28.20% increase compared to ¥26,087,054.66 in the same period last year[4] - The net profit attributable to shareholders was -¥11,808,403.41, a significant decline from -¥2,630,474.68 in the previous year, indicating a worsening financial performance[4] - The basic and diluted earnings per share were both -¥0.17, reflecting a decline from -¥0.04 in the same period last year[4] - The weighted average return on equity was -0.56%, a decrease of 0.44 percentage points from -0.12% in the previous year[4] - Net loss for Q1 2025 was CNY 11,808,403.41, compared to a net loss of CNY 2,630,474.68 in Q1 2024, indicating a significant increase in losses[19] - Operating profit for Q1 2025 was reported at CNY -15,553,406.18, worsening from CNY -4,997,646.70 in Q1 2024[18] Cash Flow - The net cash flow from operating activities was -¥13,275,293.49, a decrease of 275.64% compared to ¥7,558,148.81 in the same period last year[4] - Cash flow from operating activities in Q1 2025 was CNY 30,084,732.40, down from CNY 39,202,846.49 in Q1 2024, reflecting a decrease of 23.2%[21] - Cash inflow from operating activities totaled $30,995,341.75, while cash outflow was $44,270,635.24, leading to a negative cash flow[22] - The net increase in cash and cash equivalents for the period was $40,360,538.09, a significant decrease from $529,041,189.60 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,214,208,460.08, a slight decrease of 0.18% from ¥2,218,110,499.82 at the end of the previous year[5] - Total liabilities increased to CNY 121,652,748.93 from CNY 116,442,779.95, marking a rise of 4.0%[16] - The company's equity attributable to shareholders was ¥2,092,555,711.15, down 0.43% from ¥2,101,667,719.87 at the end of the previous year[5] Research and Development - Research and development expenses totaled ¥13,318,794.20, up 21.07% from ¥11,000,774.78, accounting for 39.82% of operating revenue[5] - Research and development expenses for Q1 2025 were CNY 13,318,794.20, up 21.0% from CNY 11,000,774.78 in Q1 2024, indicating a focus on innovation[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,887[9] - There were no significant changes in the top 10 shareholders or their shareholding percentages compared to the previous period[11] - The company’s repurchase account held 360,337 shares, accounting for 0.51% of the total share capital[11] Government Support - The company received government subsidies amounting to ¥275,849.48, which are closely related to its normal business operations[6] Inventory and Receivables - Accounts receivable rose to ¥62,916,585.14 from ¥59,959,090.49, indicating an increase of about 4.9%[14] - Inventory decreased to ¥70,609,687.64 from ¥76,083,001.99, showing a reduction of about 7.1%[14] - The total current assets decreased slightly to ¥1,934,663,394.24 from ¥1,956,275,857.23, reflecting a decline of approximately 1.1%[14] - The company reported a significant increase in receivables financing, which rose to ¥5,988,871.00 from ¥2,061,250.00, marking an increase of about 190%[14] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[23] - The company has not disclosed any new product developments or market expansion strategies during the reporting period[12]